DAIICHI SANKYO GROUP, a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and the Americas. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the group has since achieved significant milestones, including advancements in oncology and cardiovascular treatments. Specialising in innovative medicines, DAIICHI SANKYO is renowned for its unique drug development capabilities, particularly in targeted therapies and biologics. The company’s commitment to research and development has positioned it as a leader in the pharmaceutical market, with notable achievements such as the successful launch of several blockbuster drugs. With a strong focus on improving patient outcomes, DAIICHI SANKYO continues to make strides in the healthcare sector, solidifying its reputation as a trusted name in pharmaceuticals.
How does DAIICHI SANKYO GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
DAIICHI SANKYO GROUP's score of 58 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, DAIICHI SANKYO GROUP reported total carbon emissions of approximately 4,430,241,000 kg CO2e, with significant contributions from Scope 3 emissions at about 4,430,241,000 kg CO2e, while Scope 1 and Scope 2 emissions were reported at 250,060 kg CO2e and 3,360 kg CO2e, respectively. This data reflects a comprehensive approach to emissions reporting, including all relevant scopes. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions by FY2050. This long-term goal is supported by a near-term target to reduce absolute Scope 1 and Scope 2 emissions by 63% by FY2030 from a FY2015 baseline. Additionally, DAIICHI SANKYO has committed to increasing its sourcing of renewable electricity from 4% in FY2015 to 100% by FY2030, and ensuring that 70.6% of its suppliers by emissions will have science-based targets by FY2025. DAIICHI SANKYO's targets are aligned with the Science Based Targets initiative (SBTi), which includes a commitment to reduce Scope 1 and Scope 2 emissions by 37.5% by 2030 from a 2015 base year. The company is also focused on measuring and reducing its Scope 3 emissions, which represent a significant portion of its overall carbon footprint. Overall, DAIICHI SANKYO GROUP is actively working towards substantial emissions reductions and has established a framework for accountability and progress in its climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
2011 | 2012 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 182,519,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 000,000 | 000,000 |
Scope 2 | 290,715,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 0,000 | 0,000 |
Scope 3 | 5,704,000 | 0,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DAIICHI SANKYO GROUP is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.